Tekmira stock soars after FDA relaxes precautions on experimental Ebola drug

Canadian Press via Victoria (B.C.) Times Colonist

Shares of Tekmira Pharmaceuticals Corp. shot up about 47% Friday following a U.S. regulatory decision that relaxes safety precautions on the Vancouver-based company's experimental drug for treating Ebola.

Letter
to the
Editor

Send us a letter

Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

Recommended for You
U.S. Food and Drug Administration (FDA)
Upcoming FDA draft on pulse oximetry's racial bias draws questions
Most Popular
1
Humana, UnitedHealthcare, Aetna fall in new MA star ratings
2
4 nonprofit health systems launch Longitude Health
3
What’s behind a staffing crisis that just won’t quit
4
2024 Best Places to Work in Healthcare winners announced
5
Medicare Advantage insurers bank on Special Needs Plans in 2025